Aprameya Engineering IPO To Open On 25th July, Sets Price Band at Rs 56 to Rs 58 Per Share

Ahmedabad (Gujarat) [India] July 20 : Incorporated in September 2003, Aprameya Engineering Limited is engaged in Healthcare Infrastructure & supply of need based high value medical equipment like installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centres. The company is poised for its initial public offering (IPO), with plans to raise INR 29.23 crores through the issuance of 50.4 lakh new shares.

For its SME Initial Public Offering (IPO), Aprameya Engineering Limited has established a price band of Rs 56 to Rs 58 per share. The company’s shares will open for subscription on Thursday, July 25, 2024 and closes on Monday, July 29, 2024. These will be listed on the NSE SME, with a projected listing date of Thursday, August 1, 2024.
 
 Company has revenue from operation of Rs. 65.62 Crores with 10.07% EBITDA Margin and 5.30% PAT Margin. 71% Revenue contribution from healthcare infra projects for the period FY 2024.

 It has earned Rs. 235 Cr+ from healthcare infrastructure projects during FY21 to FY24 and installed 2000+ Critical Care beds since 2020. It has PAN India customer reach including Private Hospitals, AIIMS, Government Hospitals, Medical practitioners, Diagnostic centers etc. In FY-23, Company has successfully set up, installed, and commissioned 175 dialysis centers across Rajasthan in government run hospitals, with a project value of INR 31.43 crores.

Since 2020, the company has been setting up ICUs and operation theatres and has installed around 2000 critical care beds, including ICUs, NICUs, and PICUs, Modular operation theatres are being established throughout the state of Rajasthan. The company has four warehouses: two in Memnagar, Ahmedabad, one in Prahladnagar, Ahmedabad and the fourth one on Ashram Road, Ahmedabad.

Hem Securities Limited is the book running lead manager of the Aprameya Engineering IPO, while Link Intime India Private Ltd is the registrar for the issue.

The issue proceeds will be utilized to meet working capital requirements (including augmentation on Long-Term Working Capital) and general corporate purposes.

On Tuesday, July 30, 2024, the shares for the Aprameya Engineering IPO are anticipated to be allotted, and on Wednesday, July 31, 2024, the shares will be credited to the demat account of the allottees. The IPO comprises 50% of the net issue for QIB, 35% for retail investors and 15% of the net issue for the NII segment.

Retail investors need to contribute a minimum of Rs 1.16 lakh considering the minimum lot size for an application is 2000 shares. For HNIs, the minimum bidding size is two lots, or 4000 shares, for a total investment of Rs 2.32 lakh at the upper price band.

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More